Venture Debt: Device Financing Lifeline or Anchor?

Venture debt has become an increasingly popular financing option particularly among device companies. But, if not used properly, it can help sink rather than save a start-up.

In the fall of 2004, veteran device executive Allan May, then President and CEO of peripheral device start-up Vascular Architects Inc. (VA), was chairing a board meeting discussing possible financing options for the struggling company when two of his venture investors suggested that VA consider using venture debt. May was no stranger to a variety of financing options—he had been CEO or chairman of more than a half-dozen medical device start-ups. But by his own admission, he wasn’t familiar with venture debt, nor were several of the company’s other investors. Based on his investors’ suggestion, May contacted Maurice Werdegar, a partner with San Jose-based Western Technology Investment (WTI), a pioneer in providing venture debt, particularly to life science companies, and the two struck a deal that enabled May to finance the company toward a target of profitability. Things did not go as planned, however, and the two ultimately worked closely together to keep the company afloat long enough to negotiate a successful trade sale of the failing company’s assets—avoiding what otherwise looked to be likely bankruptcy.

Vascular Architects represents an extreme example of how young companies have turned to venture debt to help either stay afloat—in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.